Japanese Journal of Clinical Oncology, Vol 28, Issue 12 740-744, Copyright © 1998 by Foundation for Promotion of Cancer Research
T Yamaguchi, Y Yamamoto, S Yokota, M Nakagawa, M Ito and T Ogura
BACKGROUND: Involvements of interleukin-6 (IL-6) and fibrinogen in cancer
development have been independently studied. However, the association of
these molecules in cancer patients remains uncertain. This study was
conducted to clarify the association according to the clinicopathological
characteristics of lung cancer patients. METHODS: Serum IL-6 levels assayed
in 339 patients without pleural effusion were assessed according to
clinical stage, histological type of the cancer and levels of fibrin (ogen)
degradation products (FDP), and C-reactive protein (CRP). RESULTS:
Elevations of serum IL-6 levels more than 4 pg/ml were found in 37.8% of
all patients. According to the clinical stage and histological type, the
elevations were significantly more frequent in the advanced stage (44.7%),
in squamous cell (49.1%) and large cell carcinomas (63.6%). Similarly, the
frequency of the elevated cases (> 400 mg/dl) and the mean value of the
fibrinogen level were also higher in the advanced stage (54.2%, 455.0
mg/dl) and large cell carcinoma (54.6%, 459.3 mg/dl), respectively. The
elevations of fibrinogen, FDP and CRP levels were found to be related to
those of the IL-6 level. CONCLUSION: In lung cancer, serum IL-6 elevations
are particularly frequent in the advanced stages of patients with squamous
cell and large cell carcinoma, which are associated with the elevated
levels of fibrinogen, suggesting a possibility that IL-6 was involved not
only directly, but also indirectly, through regulating plasma fibrinogen
with promotion of cancer development in vivo.
ORIGINAL ARTICLE
Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients
Department of Internal Medicine, Toneyama National Hospital, Osaka, Japan. yamaguct@toneyama.hosp.go.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Enewold, L. E. Mechanic, E. D. Bowman, Y.-L. Zheng, Z. Yu, G. Trivers, A. J. Alberg, and C. C. Harris Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 215 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pignatelli, C.-Q. Li, P. Boffetta, Q. Chen, W. Ahrens, F. Nyberg, A. Mukeria, I. Bruske-Hohlfeld, C. Fortes, V. Constantinescu, et al. Nitrated and Oxidized Plasma Proteins in Smokers and Lung Cancer Patients Cancer Res., January 1, 2001; 61(2): 778 - 784. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Yamaguchi, H. Kimura, S. Yokota, Y. Yamamoto, T. Hashimoto, M. Nakagawa, M. Ito, and T. Ogura Effect of IL-6 Elevation in Malignant Pleural Effusion on Hyperfibrinogenemia in Lung Cancer Patients Jpn. J. Clin. Oncol., February 1, 2000; 30(2): 53 - 58. [Abstract] [Full Text] [PDF]
|
|